John A. McLane, PhD
TOLMAR, Inc., Fort Collins, COAuthored Items
Julie Prettyman, RN, BSN, CCRC, John A. McLane, PhD, Stuart N. Atkinson, MB, ChB, Allison Tyler, RN, BSN, OCN, CCRP, Deborah M. Boldt-Houle, PhD
November 2018 Vol 9, NO 11
In prostate cancer therapy, achieving and maintaining effective testosterone (T) suppression to the level attained with surgical castration is the cornerstone of androgen deprivation therapy (ADT).
Last modified: December 19, 2018